About the memorial lecture honorees:
 

• Clive Kearon (1957 – 2020)
  Clive Kearon, M.D., Ph.D., was a world-renowned expert in venous thromboembolism, conducting clinical trials that informed clinical practice with respect to the diagnosis of venous thromboembolism, the duration and intensity of anticoagulant therapy for its treatment, and the role of thrombophilia testing. He was appointed chair of the highly cited guidelines for the treatment of venous thromboembolism published by the American College of Chest Physicians. Kearon served as Director for the Clinician Investigator Program at McMaster University for many years, mentoring the next generation of clinician-scientists.

• Alan Randolph Giles (1940 – 2022)
  Alan R. Giles, M.D., established a highly innovative and productive hemostasis and thrombosis program at Queen’s University (Canada) including the second hemophilic dog colony in the world, which have been an invaluable asset for the development of novel hemophilia therapies, leading to major advances in recombinant Factor VIII therapy and the foundation for future ground-breaking gene therapy studies. Numerous aspiring clinicians and scientists from around the world would train in Alan’s lab over the years and become haemostasis and thrombosis leaders in their own right.

• Mary Patricia (Patti) Massicotte (1955 – 2020)
  Patti Massicotte, M.D., was an active clinician-researcher, contributing significantly to the field of pediatric thrombosis and anticoagulation, including her role in the REVIVE and PROTEKT studies, which set the standard for randomized controlled trials of anticoagulation prevention and treatment strategies in children for nearly two decades. Through a collaboration, Massicotte also influenced warfarin management for children through her involvement with the EMPOWERMENT studies. She was passionate about mentoring and conducting research to improve clinical outcomes for children.

• Paul Frenette (1965 – 2021)
  Paul Frenette, M.D., was a stalwart champion for medical research and for ensuring translation of his discoveries to the clinic for the benefit of patients with intractable medical conditions, including acute myeloid leukemia, prostate cancer, and sickle cell disease. His lab’s early work on selectins led to transformative treatments for vaso-occlusion in patients with sickle cell disease (SCD). He worked closely with physicians and drug companies to foster this finding into meaningful action, which culminated in the 2019 approval of an anti-P-selectin antibody for the treatment of SCD vaso-occlusion. Due to his attention to detail, Paul’s group made another unexpected seminal discovery that the nervous system regulated hematopoietic stem cell (HSC) behavior. This work thrust him to the forefront of the HSC niche field where he quickly became a rising star and leader.

​​